Initial experience with golimumab in clinical practice for ulcerative colitis

• Luisa Castro-Laria ^[1] ; Federico Argüelles-Arias ^[1] ; Valle García-Sánchez ^[2] ; José Manuel Benítez ^[2] ; Ramón Fernández-Pérez ^[3] ; Ana María Trapero-Fernández ^[3] ; Francisco Gallardo-Sánchez ^[4] ; Héctor Pallarés-Manrique ^[5] ; María Gómez-García ^[7] ; María José Cabello-Tapia ^[7] ; Aurora Talavera-Fabuel ^[6] ; Ana Bejarano-García ^[6] ; Eduardo Leo-Carnerero ^[8] ; Álvaro Hernández-Martínez ^[9] ; Ángel Caunedo-Álvarez ^[1] ; Juan Manuel Herrerías-Gutiérrez ^[1]
  1. [1] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  2. [2] Hospital Reina Sofía

     Hospital Reina Sofía

     Tudela, España

     
  3. [3] Hospital Universitario de Jaén

     Hospital Universitario de Jaén

     Jaén, España

     
  4. [4] Hospital de Poniente

     Hospital de Poniente

     Almería, España

     
  5. [5] Hospital Juan Ramón Jiménez

     Hospital Juan Ramón Jiménez

     Huelva, España

     
  6. [6] Hospital Infanta Elena

     Hospital Infanta Elena

     Huelva, España

     
  7. [7] Hospital Virgen de las Nieves. Granada
  8. [8] Hospital Virgen del Rocío. Sevilla
  9. [9] Hospital Torrecárdenas. Almería

  Mostrar afiliaciones +
• Localización: Revista Española de Enfermedades Digestivas, ISSN-e 2340-4167, ISSN 1130-0108, Vol. 108, Nº. 3, 2016, págs. 129-132
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Background: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis.

    Purpose: To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice.

    Methods: Retrospective study of the effectiveness and safety of golimumab in patients with ulcerative colitis. All patients received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each patient received 50 mg sc. every 4 weeks in patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients with body weight greater than or equal to 80 kg.

    Results: Study of a group of 23 ulcerative colitis patients, 7 of whom were naive to any anti-TNF therapy, and 16 patients who had previously been treated with an anti-TNF agent other than golimumab (non-naive patients). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids was observed in 74% of cases. Clinical response was observed in 85.5% of patients who had not received biological treatment previously, and in patients who had previously received biological treatment the response rate was 75%.

    Conclusions: In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients. It is also a safe therapy, given that there were no adverse effects in the patients studied.